The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications

Digestive Diseases and Sciences

Volumn 50, Issue 10, 2005, Pages 1909-1915

  Bautista, Jimmy M ^a   Wong, Wai Man ^a   Pulliam, Gloria ^a   Esquivel, Romeo F ^a   Fass, Ronnie ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

Esophageal pH monitoring; Gastroesophageal reflux disease; Proton pump inhibitor

Indexed keywords

ACID; CIMETIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; CHEMORECEPTOR; CLINICAL PRACTICE; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PERFUSION; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HISTAMINE H2 ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; MONITORING, AMBULATORY; PROTON PUMPS; REFERRAL AND CONSULTATION; REPRODUCIBILITY OF RESULTS; TREATMENT FAILURE;

EID: 26244458987     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2960-7     Document Type: Article

References (44)

1. Hunt RH: Importance of pH control in the management of GERD. Arch Intern Med 159:649-657, 1999
2. Sifrim D, Holloway R, Silny J, Xin Z, Tack J, Lerut A, Janssens J: Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24 hr pH-impedance recordings. Gastroenterology 120:1862-1864, 2001
3. Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO: Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 120:1599-1606, 2001
4. Tack J, Fass R: Approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder? Aliment Pharmacol Ther 19:28-34, 2004
5. Fass R: Gastroesophageal reflux disease revisited. Gastroenterol Clin North Am 31:S1-S10, 2002
6. Leite LP, Johnston BT, Just RJ, Castell DO: Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 91:1527-1531, 1996
7. Klinkenberg-Knol EC, Meuwissen SG: Combined gastric and oesophageal 24 hr pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment Pharmacol Ther 4:485-495, 1990
8. Savarino V, Mela GS, Zentilin P, Celle G: Is gastric acid hypersecretion the only reason for refractory gastroesophageal reflux disease? Gastroenterology 99, 1990
9. Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K, de Groot G, van Oudvorst A, Dalvag A, Junghard O, Wiklund I: Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 10:119-124, 1998
10. Fass R, Fennerty MB, Vakil N: Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol 96:303-314, 2001
11. Fass R: Epidemilogy and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 98:S2-S7, 2003
12. Kahrilas PJ, Quigley EM: American Gastroenterological Association Medical Position Statement: guidelines on the use of esophageal pH recording. Gastroenterology 110:1981-1996, 1996
13. Dekel R, Malagon IB, Green C, Fass R: Abstract: Comparison of transnasaly placed wireless pH capsule (BRAVO) versus traditional 24 hr esophageal pH monitoring - A randomized trial. Am J Gastroenterol 98(108):S38, 2003
14. Wiener GJ, Morgan TM, Copper JB, Wu WC, Castell DO, Sinclair JW, Richter JE: Ambulatory 24 hr esophageal pH monitoring. Reproducibility and variability of pH parameters. Dig Dis Sci 33:1127-1133, 1988
15. Richter JE, Hewson EG, Sinclair JW, Dalton CB: Acid perfusion test and 24 hr esophageal pH monitoring with symptom index. Comparison of tests for esophageal acid sensitivity. Dig Dis Sci 36:565-571, 1991
16. Wiener GJ, Richter JE, Copper JB, Wu WC, Castell DO: The symptom index: a clinically important parameter of ambulatory 24 hr esophageal pH monitoring. Am J Gastroenterol 83:358-361, 1988
17. Trimble KC, Pryde A, Heading RC: Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 37:7-12, 1995
18. Hobson A, Matthews P, Furlong P, Qasim A: Abstract: The role of esophageal afferent pathway sensitivity in non-erosive reflux disease. Gastroenterology 4(128):A-18, 2004
19. Gracely RH, McGrath P, Dubner R: Ratio scales of sensory and affective verbal pain descriptors. Pain 5:5-18, 1978
20. Silverman DH, Munakata JA, Ennes H, Mandelkern MA, Hoh CK, Mayer EA: Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 112:64-72, 1997
21. Dekel R, Morse C, Fass R: The role of proton pump inhibitors in gastro-oesophageal reflux disease. Drugs 64:277-295, 2004
22. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II and IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112:1798-1810, 1997
23. Vaezi MF, Charbel S: Abstract: On-therapy pH monitoring: usually recommended but should we do it? Gastroenterology 126(640):A-82, 2004
24. Levy AH, Benwait KS, DiMarino AJ, Cohen S: Abstract: Utility of twenty-four hour esophageal pH monitoring in patients with persistent symptoms on PPI therapy. Gastroenterology 126(132):A-19, 2004
25. Steinbach J, Fass R, Mittal R: Assessment of relationship between acid reflux and heartburn suing receiver operating characteristics curves. Gastroenterol Clin North Am 31:S35-S58, 2002
26. Katz PO: Editorial: Diagnosis and therapy of noncardiac chest pain: a clinical dilemma. J Clin Gastroenterol 35:292-294, 2002
27. Fass R, Ofman J, Sampliner RE, Camargo L, Wendel C, Fennerty MB: The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive esophagitis. Aliment Pharmacol Ther 14:389-396, 2000
28. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Tubitt ML: Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 32:965-973, 1997
29. Cloud ML, Offen WW, Robinson M: Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study. Am J Gastroenterol 86:1735-1742, 1991
30. Sabesin SM, Berline RG, Humphries TJ, Bradstreet DC, Walton-Bowen KL, Zaidi S: Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group. Arch Intern Med 151:2394-2400, 1991
31. Kahrilas PJ, Fennerty MB, Joelsson B: High- versus standard dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol 94:92-97, 1999
32. Fass R, Murthy U, Hayden CW, Malagon IB, Pulliam G, Wendel C, Kovacs TO: Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy - a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 14:1595-1603, 2000
33. Fass R, Tougas G: Functional heartburn: the stimulus, the pain, and the brain. Gut 51:885-892, 2002
34. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 97:575-583, 2002
35. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ: Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 13:49-57, 1999
36. Mossner J, Holscher AH, Herz R, Schneider A: A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 9:321-326, 1995
37. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D'Amico D, Hamelin B, Joelsson B: Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 14:1249-1258, 2000
38. Dean BB, Gano A, Jr, Knight K, Ofman J, Fass R: Effectiveness of proton pump inhibitors in non-erosive reflux disease (NERD). Clin Gastroenterol Hepatol 2:656-664, 2004
39. Lind T, Havelund T, Carlsson R: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 32:974-979, 1997
40. DeMeester TR, Wang CI, Wenly JA, Pellegrini CA, Little AG, Klementschitsch P, Bermudez G, Johnson LF, Skinner DB: Technique, indications, and clinical use of 24 hr esophageal pH monitoring. J Thorac Cardiovasc Surg 79:656-670, 1980
41. Schenk BE, Juipers EJ, Klinkenberg-Knol EC, Festen HP, Jansen EH, Tuynman HA, Schrijver M, Dieleman LA, Meuwissen SG: Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 92:1997-2000, 1997
42. Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC: Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 40:1607-1613, 1995
43. Pehlivanov N, Liu J, Mittal R: Sustained esophageal contraction: a motor correlate of heartburn symptom. Am J Physiol Gastrointest Liver Physiol 281:G743-G751, 2001
44. Tack J, Koek G, Demedts I, Sifrim D, Janssens J: Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: reflux, bile reflux, or both? Am J Gastroenterol 99:981-990, 2004